Development
Kyowa Kirin and Amgen terminate rocatinlimab trials over malignancy signal in atopic dermatitis
Japan-based Kyowa Kirin Co., Ltd. and partner Amgen have discontinued all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody that...
Sensorion pushes AAV gene therapy targeting connexin 26 mutations toward clinic for most common genetic deafness
Sensorion, a French clinical-stage biotechnology company, announced on March 23, 2026, that it is advancing SENS-601 (GJB2-GT), an AAV-based gene therapy...
City Therapeutics Launches Phase 1 Trial of CITY-FXI siRNA for Inherited Thrombophilia
City Therapeutics, Inc. has begun dosing participants in a Phase 1 clinical trial of CITY-FXI, a small interfering RNA (siRNA) that targets Factor XI (FXI)...
Akeso's first-in-class trispecific antibody hits ILT2, ILT4, and CSF1R to dismantle myeloid immunosuppression in solid tumors
Akeso's trispecific antibody AK150, which simultaneously targets the immunosuppressive receptors ILT2, ILT4, and CSF1R, has received Investigational New...
Insmed's Arikayce meets primary endpoint in Phase IIIb ENCORE study for MAC lung disease
Insmed (Nasdaq: INSM) reported that its Phase IIIb ENCORE study of Arikayce (amikacin liposome inhalation suspension) met its primary endpoint and all...
Whitehawk Therapeutics Launches Phase 1 First-in-Human Trial of MUC16-Directed ADC HWK-016 in Ovarian Cancer
Whitehawk Therapeutics has begun recruiting patients into a Phase 1 first-in-human clinical trial (NCT07470853) of HWK-016, a MUC16-directed antibody-drug...
Roche halts emugrobart development in spinal muscular atrophy after MANATEE study fails
Roche has discontinued development of emugrobart (GYM329), an investigational anti-myostatin antibody, in spinal muscular atrophy after Part 1 of the Phase...
PBS293-MMAE preclinical data from Promatix Biosciences show promise in colorectal cancer models
UK-based Promatix Biosciences announced preclinical data for PBS293-MMAE, a first-in-class cis-bispecific antibody-drug conjugate targeting both EGFR and...
Cyrano Therapeutics' CYR-064 shows positive Phase II results in persistent post-viral smell loss
Florida-based Cyrano Therapeutics announced positive topline results from its Phase II FLAVOR trial evaluating CYR-064, an intranasal broad-spectrum...
Dizal's sunvozertinib beats chemotherapy in Phase III first-line EGFR exon 20 insertion NSCLC trial
Dizal (SSE:688192) reported that its Phase III WU-KONG28 trial of sunvozertinib (Zegfrovy) met its primary endpoint in first-line NSCLC harboring EGFR exon...
Dizal's sunvozertinib achieves 81% response rate as first-line therapy in EGFR PACC-mutant NSCLC
Dizal (SSE:688192) reported new clinical data for sunvozertinib NSCLC at the 2026 European Lung Cancer Congress in Copenhagen, showing an 81.3% objective...
Roche's Gazyva achieves positive phase III results in primary membranous nephropathy trial
Roche announced that the Phase III MAJESTY study evaluating Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy met its primary endpoint, with...
argenx reports positive Phase 3 results for efgartigimod in ocular myasthenia gravis trial
Netherlands-based argenx SE announced positive topline results from the Phase 3 ADAPT OCULUS trial evaluating VYVGART (efgartigimod alfa and...
Priavoid presents blinded interim safety data for PRI-002 in Alzheimer's disease Phase II trial
Priavoid GmbH, a Dusseldorf-based biotech, presented blinded interim safety data from its ongoing Phase II trial of PRI-002 in Alzheimer's disease at the...
Centivax Doses First Participants in Phase 1 Trial of Centi-Flu 01 Universal Influenza Vaccine
Centivax, Inc., a South San Francisco–based biotechnology company, has dosed the first participants in a Phase 1A clinical trial of Centi-Flu 01, a...
The AllSci Brief
Systematic R&D and deal news. Daily.